Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
80 pending office actions • 28 art units • 73 examiners • 1 of 80 (1%) have an AI response strategy ready • 67 patents granted in the last 365 days
Novartis AG maintains 75 pending office actions in the Biotechnology & Pharmaceuticals technology area. These actions are distributed across 28 distinct art units, indicating a pharmaceutical focus. The portfolio involves 67 distinct examiners, requiring the management of many unique examiner relationships.
Fubara, Blessing M is the busiest examiner with 2 pending office actions. Despite having 75 pending office actions, the workload is spread so that 67 distinct examiners are involved. This distribution across 28 distinct art units suggests that Novartis AG faces a diverse set of examination challenges across its biotech and pharmaceutical applications.
Based on the USPTO statutory response window for each pending office action. 24 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 24 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 2 (2%) |
| §103 only | 15 (19%) |
| §102 only | 2 (2%) |
| §112 only | 6 (8%) |
| Double-patenting only | 5 (6%) |
| Double-patenting + other | 24 (30%) |
| Multi-statute (no §101) | 26 (32%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| FUBARA, BLESSING M | 2 | 62.2% | +34.2% |
| BENAVIDES, JENNIFER ANN | 2 | 51.2% | +47.0% |
| SZPERKA, MICHAEL EDWARD | 2 | 62.7% | +37.1% |
| SAMALA, JAGADISHWAR RAO | 2 | 67.9% | +55.7% |
| AEDER, SEAN E | 2 | 56.9% | +20.0% |
| HOWARD, ZACHARY C | 2 | 63.9% | +37.6% |
| WANG, CHANG YU | 2 | 33.5% | +53.6% |
| DUTT, ADITI | 1 | 46.9% | +48.1% |
| PERREIRA, MELISSA JEAN | 1 | 52.0% | +25.8% |
| MEJIAS, SAMANTHA LEE | 1 | 46.4% | +40.9% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17766149 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | SCHMIDT, IZABELA MARIA | 264d overdue |
| 18015856 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | CHICKS, ASHLI ARIANA | 133d overdue |
| 18561444 | FORMULATIONS OF 3-((3-(4-(2-(ISOBUTYLSULFONYL)PHENOXY)-3-(TRIFLUOROMETHYL)PHENYL)-1,2,4-OXADIAZOL-5-YL)METHYL)-5,5-DIMETHYL-1-(2-MORPHOLINOETHYL)IMIDAZOLIDINE-2,4-DIONE | RAO, SAVITHA M | 8d overdue |
| 17997137 | CCR7 ANTIBODY DRUG CONJUGATES FOR TREATING CANCER | SKOKO III, JOHN JOSEPH | 14d |
| 18261523 | PHARMACEUTICAL COMPOSITION | GOTFREDSON, GAREN | 27d |
| 18286030 | OFATUMUMAB FOR TREATING MULTIPLE SCLEROSIS IN ASIAN PATIENTS | CHHAY, BONIRATH | 34d |
| 18187242 | USE OF CANAKINUMAB | HOWARD, ZACHARY C | 34d |
| 19176436 | PHARMACEUTICAL COMPOSITIONS OF RIBOCICLIB | YOUNG, MICAH PAUL | 41d |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18440783 | LABELED INHIBITORS OF PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA) AS AGENTS FOR THE TREATMENT OF PROSTATE CANCER | SAMALA, JAGADISHWAR RAO | 91d overdue |
| 18977210 | Ribociclib Tablet | FUBARA, BLESSING M | 88d overdue |
| 17753635 | Management of conditions other than multiple sclerosis in ofatumumab-treated patients | WANG, CHANG YU | 60d overdue |
| 18251913 | ANTIBODY Fc VARIANTS | HOWARD, ZACHARY C | 37d overdue |
| 17995820 | OFATUMUMAB FOR TREATING MS WHILE MAINTAINING SERUM IgG | WANG, CHANG YU | 35d overdue |
| 19240908 | METHOD OF TREATING PROSTATE CANCER | PERREIRA, MELISSA JEAN | 32d overdue |
| 18187242 | USE OF CANAKINUMAB | HOWARD, ZACHARY C | 34d |
| 19234864 | STABLE, CONCENTRATED RADIOPHARMACEUTICAL COMPOSITION | MEJIAS, SAMANTHA LEE | 76d |
| Art Unit | Apps |
|---|---|
| 1675 | 7 |
| 1618 | 7 |
| 1674 | 6 |
| 1643 | 4 |
| 1647 | 3 |
| 1613 | 2 |
| 1628 | 2 |
| 1623 | 2 |
| 1646 | 2 |
| 1625 | 2 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19575321 | THERAPEUTIC ANTI-BAFF-R ANTIBODIES | DUTT, ADITI | 1675 | DP | Non-Final OA | — | Pending | Mar 23, 2026 |
| 19240908 | METHOD OF TREATING PROSTATE CANCER | PERREIRA, MELISSA JEAN | 1618 | §103DP | Non-Final OA | 32d overdue | Pending | Jun 17, 2025 |
| 19234864 | STABLE, CONCENTRATED RADIOPHARMACEUTICAL COMPOSITION | MEJIAS, SAMANTHA LEE | 1618 | §103Other | Final Rejection | 76d | Pending | Jun 11, 2025 |
| 19176436 | PHARMACEUTICAL COMPOSITIONS OF RIBOCICLIB | YOUNG, MICAH PAUL | 1618 | §102§103 | Non-Final OA | 41d | Pending | Apr 11, 2025 |
| 19065656 | SELECTIVE REDUCTION OF CYSTEINE RESIDUES IN IL-17 ANTIBODIES | ABBAS, SYED JARAR | 1674 | §112 | Final Rejection | — | Pending | Feb 27, 2025 |
| 18977210 | Ribociclib Tablet | FUBARA, BLESSING M | 1613 | §103DP | Final Rejection | 88d overdue | Pending | Dec 11, 2024 |
| 18871590 | CRYSTALLINE FORMS OF AN AKRIC3 DEPENDENT KARS INHIBITOR | MOORE, SUSANNA | — | §102§112DP | Non-Final OA | — | Pending | Dec 04, 2024 |
| 18960021 | NEW CRYSTALLINE FORMS OF SALT OF 7-CYCLOPENTYL-2-(5-PIPERAZIN-1-YL-PYRIDIN-2-YLAMINO)-7H-PYRROLO[2,3-D]PYRIMIDINE -6-CARBOXYLIC ACID DIMETHYLAMIDE | WHITE, DAWANNA SHAR-DAY | — | §103DP | Non-Final OA | — | Pending | Nov 26, 2024 |
| 18939314 | PYRAZOLOPYRIDINE DERIVATIVES AND USES THEREOF | KUCHARCZK, JED A | — | §112DP | Non-Final OA | — | Pending | Nov 06, 2024 |
| 18909652 | NLRP3 INFLAMMASOME INHIBITORS | COUGHLIN, MATTHEW P | — | §102§103Other | Non-Final OA | — | Pending | Oct 08, 2024 |
| 18851253 | COMPLEMENT FACTOR B INHIBITORS AND USES THEREOF | BARSKY, JARED | — | §112 | Non-Final OA | — | Pending | Sep 26, 2024 |
| 18687609 | CRYSTALLINE FORMS OF BIARYL YAP/TAZ-TEAD PROTEIN-PROTEIN INTERACTION INHIBITORS | CLARK, AMY LYNN | — | §102§103§112Other | Non-Final OA | — | Pending | Sep 24, 2024 |
| 18843599 | USE OF IPTACOPAN FOR THE TREATMENT OF LUPUS NEPHRITIS | SHI, GENBIN | — | §103§112 | Non-Final OA | — | Pending | Sep 03, 2024 |
| 18802089 | IMMUNOSUPPRESSANT FORMULATIONS | ROSENTHAL, ANDREW S | — | §103 | Final Rejection | — | Pending | Aug 13, 2024 |
| 18800559 | COMPOUNDS AND COMPOSITIONS FOR MODULATING THE ACTIVITY OF ERK | REILLY, SOPHIA JANE | — | §102§112 | Non-Final OA | — | Pending | Aug 12, 2024 |
| 18797888 | Octreotide Depot Formulation with Constantly High Exposure Levels | WESTERBERG, NISSA M | — | §112DP | Non-Final OA | — | Pending | Aug 08, 2024 |
| 18797142 | NAPHTHYRIDINONE DERIVATIVES FOR THE TREATMENT OF A DISEASE OR DISORDER | WARD, PAUL V | — | DP | Non-Final OA | — | Pending | Aug 07, 2024 |
| 18729949 | SPIROCYCLIC PIPERIDINYL DERIVATIVES AS COMPLEMENT FACTOR B INHIBITORS AND USES THEREOF | FETTEROLF, BRANDON J | — | §102 | Non-Final OA | — | Pending | Jul 18, 2024 |
| 18739657 | COMBINATION | HUI, SAN MING R | — | §103 | Non-Final OA | — | Pending | Jun 11, 2024 |
| 18672871 | ANTIBODIES TO PMEL17 AND CONJUGATES THEREOF | BENAVIDES, JENNIFER ANN | 1675 | §102§103§112DP | Non-Final OA | — | Pending | May 23, 2024 |
| 18670859 | NAPHTHYRIDINONE DERIVATIVES FOR THE TREATMENT OF A DISEASE OR DISORDER | PATEL, SAGAR S | — | §112Other | Non-Final OA | — | Pending | May 22, 2024 |
| 18655058 | FACTOR XI ANTIBODIES AND METHODS OF USE | SZPERKA, MICHAEL EDWARD | — | §112DP | Non-Final OA | — | Pending | May 03, 2024 |
| 18703559 | METHODS FOR IMPROVING ADENO-ASSOCIATED VIRUS (AAV) DELIVERY | YU, DAVID TUYANG | — | §102§103§112 | Non-Final OA | — | Pending | Apr 22, 2024 |
| 18628097 | METHODS OF TREATING NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS USING INTERLEUKIN-17 (IL-17) ANTAGONISTS | CARTER, SANDRA DILLAHUNT | — | §103§112DP | Non-Final OA | — | Pending | Apr 05, 2024 |
| 18628570 | USE OF LABELED INHIBITORS OF PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA), AS AGENTS FOR THE TREATMENT OF PROSTATE CANCER | SAMALA, JAGADISHWAR RAO | 1618 | §102§112 | Final Rejection | — | Pending | Apr 05, 2024 |
| 18696753 | SURFACTANT STABILIZERS | KENYON, JOHN S | — | §102§112 | Non-Final OA | — | Pending | Mar 28, 2024 |
| 18687599 | Dosing Regimen for a TEAD inhibitor | VALENROD, YEVGENY | 1628 | §112Other | Non-Final OA | — | Pending | Feb 28, 2024 |
| 18588259 | Ribociclib Tablet | FUBARA, BLESSING M | 1613 | §102§103DP | Final Rejection | — | Pending | Feb 27, 2024 |
| 18685551 | LOU064 FOR TREATING MULTIPLE SCLEROSIS | CHAO, ALLEN | 1622 | §103 | Final Rejection | — | Pending | Feb 22, 2024 |
| 18444288 | PROTEIN SOLUTION FORMULATION CONTAINING HIGH CONCENTRATION OF AN ANTI-VEGF ANTIBODY | KIM, YUNSOO | — | §102§103DP | Non-Final OA | — | Pending | Feb 16, 2024 |
| 18683858 | OFATUMUMAB FOR TREATING PEDIATRIC MS | AEDER, SEAN E | — | §103DP | Non-Final OA | — | Pending | Feb 15, 2024 |
| 18440783 | LABELED INHIBITORS OF PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA) AS AGENTS FOR THE TREATMENT OF PROSTATE CANCER | SAMALA, JAGADISHWAR RAO | 1618 | DP | Non-Final OA | 91d overdue | Pending | Feb 13, 2024 |
| 18423776 | TRIAZOLOPYRIMIDINE COMPOUNDS AND USES THEREOF | COLEMAN, BRENDA LIBBY | 1624 | §112DP | Non-Final OA | — | Pending | Jan 26, 2024 |
| 18424004 | COMPOSITIONS AND METHODS FOR INCREASING MUSCLE GROWTH | HAMA, JOANNE | — | DP | Non-Final OA | — | Pending | Jan 26, 2024 |
| 18291083 | SUBSTITUTED PYRIDONE COMPOUNDS USEFUL TO TREAT ORTHOMYXOVIRUS INFECTIONS | LEE, WILLIAM Y | 1623 | §103§112 | Non-Final OA | — | Pending | Jan 22, 2024 |
| 18391485 | METHODS OF TREATING CHRONIC SPONTANEOUS URTICARIA USING LIGELIZUMAB | SZPERKA, MICHAEL EDWARD | — | §102§103 | Non-Final OA | — | Pending | Dec 20, 2023 |
| 18569346 | PHARMACEUTICAL FORMULATION CONTAINING AN ANTI-IgE ANTIBODY | LIU, SUE XU | 1646 | §102§103§112 | Non-Final OA | — | Pending | Dec 12, 2023 |
| 18562108 | METHODS FOR THE TREATMENT OF OSTEOARTHRITIS | METCALF, MATTHEW CURRAN | 1647 | §101§102§103DP | Non-Final OA | — | Pending | Nov 17, 2023 |
| 18561444 | FORMULATIONS OF 3-((3-(4-(2-(ISOBUTYLSULFONYL)PHENOXY)-3-(TRIFLUOROMETHYL)PHENYL)-1,2,4-OXADIAZOL-5-YL)METHYL)-5,5-DIMETHYL-1-(2-MORPHOLINOETHYL)IMIDAZOLIDINE-2,4-DIONE | RAO, SAVITHA M | 1691 | §102§103§112Other | Non-Final OA | 8d overdue | Pending | Nov 16, 2023 |
| 18559859 | DOSING REGIMENS | ENGLISH, CONNOR KENNEDY | 1625 | §103 | Non-Final OA | — | Pending | Nov 09, 2023 |
| 18558766 | IPTACOPAN FOR THE TREATMENT OF ATYPICAL HEMOLYTIC UREMIC SYNDROME | HERNANDEZ, JACKSON J | 1627 | §103DP | Final Rejection | 17d overdue | Pending | Nov 03, 2023 |
| 18558729 | TREATMENT FOR SYSTEMIC LUPUS ERYTHEMATOSUS USING ANTI-BAFFR ANTIBODIES | MCCOLLUM, ANDREA K | 1674 | §102§103§112DP | Non-Final OA | — | Pending | Nov 02, 2023 |
| 18288345 | VIRAL VECTOR PRODUCTION SYSTEM | STAVROU, CONSTANTINA E | 1632 | §102§103§112 | Non-Final OA | — | Pending | Oct 25, 2023 |
| 18286030 | OFATUMUMAB FOR TREATING MULTIPLE SCLEROSIS IN ASIAN PATIENTS | CHHAY, BONIRATH | 1645 | §102§103§112Other | Non-Final OA | 34d | Pending | Oct 06, 2023 |
| 18552760 | DIAGNOSTIC METHODS OF PROSTATE CANCER | ROGERS, JAMES WILLIAM | 1618 | §103§112 | Non-Final OA | — | Pending | Sep 27, 2023 |
| 18281732 | FATTY ACID-BIFUNCTIONAL DEGRADER CONJUGATES AND THEIR METHODS OF USE | HEASLEY, MEGHAN CHRISTINE | 1626 | §103§112Other | Non-Final OA | — | Pending | Sep 12, 2023 |
| 18550004 | HIGH THROUGHOUT SCREENING IN DROPLETS | BUNKER, AMY M | 1684 | §103 | Final Rejection | — | Pending | Sep 11, 2023 |
| 18454457 | ANTIBODIES TO PMEL17 AND CONJUGATES THEREOF | BENAVIDES, JENNIFER ANN | 1675 | §102§103§112DP | Non-Final OA | — | Pending | Aug 23, 2023 |
| 17997137 | CCR7 ANTIBODY DRUG CONJUGATES FOR TREATING CANCER | SKOKO III, JOHN JOSEPH | 1643 | §102§103§112Other | Non-Final OA | 14d | Pending | Aug 08, 2023 |
| 18261523 | PHARMACEUTICAL COMPOSITION | GOTFREDSON, GAREN | 1619 | §102§103§112Other | Final Rejection | 27d | Pending | Jul 14, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialNovartis AG has 80 pending office actions as of October 2026, spread across 28 art units and 73 examiners.
Blessing M Fubara has the most, with 2 of Novartis AG's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.